ArticlePloS one2014
Clinical risk factors associated with anti-epileptic drug responsiveness in canine epilepsy.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 1 synthesis or guideline pooled it, 63 citations in OpenAlex.
- Treatment in canine epilepsy--a systematic review.BMC veterinary research · 2014Pooled it
- Pharmacokinetics of rectal levetiracetam as add-on treatment in dogs affected by cluster seizures or status epilepticus.BMC veterinary research · 2018Trial
- Clinical evaluation of a combination therapy of imepitoin with phenobarbital in dogs with refractory idiopathic epilepsy.BMC veterinary research · 2017Trial
- Efficacy, safety, and tolerability of imepitoin in dogs with newly diagnosed epilepsy in a randomized controlled clinical study with long-term follow up.BMC veterinary research · 2015Trial
- Prevalence and potential risk factors associated with idiopathic epilepsy in Golden Retrievers.Journal of veterinary internal medicine · 2026Article
- Gut microbiome alterations in canine idiopathic epilepsy: a pairwise case-control study.Animal microbiome · 2026Article
- Gut Microbiome Alterations in Canine Idiopathic Epilepsy: A Pairwise Case-Control Study.bioRxiv : the preprint server for biology · 2026Article
- Proteome profiling of cerebrospinal fluid-derived extracellular vesicles reveals potential biomarkers for drug-resistant epilepsy.Clinical proteomics · 2025Article
- Extended Analysis of Status Epilepticus and Cluster Seizures in Dogs in the Context of Overall Epilepsy Incidence: 254 Cases.Animals : an open access journal from MDPI · 2025Article
- In-hospital evaluation of an app-based seizure detection system in dogs: timely detection of generalized tonic-clonic seizures.Frontiers in veterinary science · 2025Article
- Scalp electrode placement accuracy for the canine electroencephalography array.Frontiers in veterinary science · 2025Article
- Caregiver-reported increased food motivation and adiposity in dogs receiving antiseizure drugs.The Veterinary record · 2024Article
- Re-evaluating the placebo response in recent canine dietary epilepsy trials.BMC veterinary research · 2024Article
- Behavioral comorbidities treatment by fecal microbiota transplantation in canine epilepsy: a pilot study of a novel therapeutic approach.Frontiers in veterinary science · 2024Article
- "Resistance Is Futile": A Pilot Study into Pseudoresistance in Canine Epilepsy.Animals : an open access journal from MDPI · 2023Article
- Effect of an intervention of exercise on sleep and seizure frequency in idiopathic epileptic dogs.The Journal of small animal practice · 2023Article
- Editorial: Epilepsy in veterinary science.Frontiers in veterinary science · 2023Article
- Risk factors associated with short-term mortality and recurrence of status epilepticus in dogs.Journal of veterinary internal medicine · 2022Article
- Phenotype of Idiopathic Epilepsy in Great Swiss Mountain Dogs in Germany-A Retrospective Study.Frontiers in veterinary science · 2022Article
- Pregabalin Add-On vs. Dose Increase in Levetiracetam Add-On Treatment: A Real-Life Trial in Dogs With Drug-Resistant Epilepsy.Frontiers in veterinary science · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The nature and occurrence of remission, and conversely, pharmacoresistance following epilepsy treatment is still not fully understood in human or veterinary medicine. As such, predicting which patients will have good or poor treatment outcomes is imprecise, impeding patient management. In the present study, we use a naturally occurring animal model of pharmacoresistant epilepsy to investigate clinical risk factors associated with treatment outcome. Dogs with idiopathic epilepsy, for which no underlying cause was identified, were treated at a canine epilepsy clinic and monitored following discharge from a small animal referral hospital. Clinical data was gained via standardised owner questionnaires and longitudinal follow up data was gained via telephone interview with the dogs' owners. At follow up, 14% of treated dogs were in seizure-free remission. Dogs that did not achieve remission were more likely to be male, and to have previously experienced cluster seizures. Seizure frequency or the total number of seizures prior to treatment were not significant predictors of pharmacoresistance, demonstrating that seizure density, that is, the temporal pattern of seizure activity, is a more influential predictor of pharmacoresistance. These results are in line with clinical studies of human epilepsy, and experimental rodent models of epilepsy, that patients experiencing episodes of high seizure density (cluster seizures), not just a high seizure frequency pre-treatment, are at an increased risk of drug-refractoriness. These data provide further evidence that the dog could be a useful naturally occurring epilepsy model in the study of pharmacoresistant epilepsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.